Conexeu Sciences (CNXU)
Develops temperature-responsive collagen scaffolds for wound care and tissue restoration.
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.
/PRNewswire/ -- Equity Insider News Commentary - Every so often, a wave of demand in one corner of medicine spills over and creates an entirely new market next
Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission
Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance by Q1 2027, potentially accelerating market entry to late 2027 and minimizing investor dilution. Current valuation (~$13.20/share) exceeds risk-adjusted fair value ($10.71), but premium is justified by pipeline breadth and upside if regulatory milestones are met.
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Activities are intended to support regulatory testing and the Company's planned first-quarter 2027 FDA 510(k) premarket notification submission Activities are intended to support regulatory testing and the Company's planned first-quarter 2027 FDA 510(k) premarket notification submission
UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology
Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology
Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"
Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue